Background: Infliximab (IFX) and adalimumab (ADA) refer to the classic drugs to treat moderate-severe inflammatory bowel disease (IBD), which have been proven to be effective to control IBD. However, the side effects exerted by IFX and ADA should be monitored in therapies, especially the paradoxical reaction of the skin system (e.g., psoriasis). Psoriasis is recognized as the most common skin lesion, capable of significantly affecting the quality of patients’ life. Methods: This study searched literatures published in English language with the qualifications on PubMed, Embase, Web of Science, Google, and Geenmedical databases. Over 2 co-authors assessed the quality of the articles and extracted the data independently. The data acquired were statistically analyzed with the statistical software of Revman and Stata. Results: The ADA Group achieved a higher incidence of psoriasis (odds ratio [OR] = 0.658, 95% confidence interval [CI] [0.471–0.919]); Females achieved a higher incidence of psoriasis than males (OR = 1.941, 95%CI [1.326–2.843], P < .05); Smoking up-regulated the incidence of psoriasis (OR = 1.679, 95%CI [1.237–2.279], P < .05); The interval of medication was over 1 year, and the interval of medication applying IFX was longer than that of the ADA Group; most cases could be relieved by using local hormone, phototherapy, or systemic hormone therapy under the strategy of biological agents. Conclusions: The frequency of reported in IBD exceeds those of other autoimmune diseases, and the ADA treatment for IBD is safer than IFX. Psoriasis is more common in females than in males. Smoking refers to one of risk factors of psoriasis.

Background: At present, infliximab(IFX) and adalimumab(ADA) are the classic drugs for the treatment of moderate-severe inflammatory bowel disease(IBD), which prove effective for the disease control. However, the side effects need to be monitored during the therapy process, especially the paradoxical reaction of the skin system such as psoriasis, which could greatly benefit quality of patients’ life.Aim: In order to describe and analyze TNF-antagonist-induced psoriasis in patients with inflammatory bowel disease from the aspects of incidence, pathogenesis, distribution and type of lesions, prognosis and treatment, the incidence of psoriasis induced by Infliximab (IBD) and Adalimumab (ADA) in the treatment of Inflammatory Bowel Disease Disease (IBD) as well as the relationship between sex, smoking and the incidence of psoriasis were investigated.Methods: Literatures in English language meeting the qualifications on Pubmeb, Embase, Web of Science, Google, and Geenmedical databases were searched . More than two co-authors evaluated the quality of the article and extracted the data respectively. The data obtained were statistically analyzed by statistical software of Revman and Stata.Results: 1) The incidence of psoriasis was higher in ADA Group (OR 0.66, P<0.05, 95% CI (0.52-0.84) ; 2) The incidence of psoriasis was higher in females than in males (OR 1.54, P<0.05, 95% CI (1.27-1.86)) ; 3) Smoking increased the incidence of psoriasis (OR 1.79, P<0.01, 95% CI (1.42-2.24); 4) Psoriasis is mainly distributed in the Scalp, Palmoplantar, skin folds and limbs, and often occurs in the genital organs, the pathogenesis of which is not completely clear; the interval of medication is more than one year, and the interval of medication using IFX is longer than that of ADA Group; most cases can be relieved by local hormone, phototherapy or systemic hormone therapy without changing the strategy of biological agents.Conclusion: The incidence of psoriasis induced by TNF-antagonists is higher in many autoimmune diseases. The frequency of reported in inflammatory bowel disease is higher than other autoimmune diseases, and the safety of ADA Treatment for IBD is higher than that of IFX The incidence of psoriasis is higher in women than in men; the incidence of psoriasis is significantly higher in smokers / ex-smokers than in non-smokers. The interval of drug use of TNF-antagonists may be a predictive factor for the prevention and treatment of psoriasis, and there are differences among different kinds of TNF-antagonists. Change of therapeutic strategy of TNF-antagonists is not recommended in the event of psoriasis.